NeoGenomics, Inc. (NEO)
NEO Stock Price Chart
Explore NeoGenomics, Inc. interactive price chart. Choose custom timeframes to analyze NEO price movements and trends.
NEO Company Profile
Discover essential business fundamentals and corporate details for NeoGenomics, Inc. (NEO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
16 Mar 2004
Employees
2.20k
Website
https://www.neogenomics.comCEO
Anthony Zook
Description
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
NEO Financial Timeline
Browse a chronological timeline of NeoGenomics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Jul 2026
EPS estimate is $0.03, while revenue estimate is $196.93m.
Earnings released on 28 Apr 2026
EPS came in at $0.01 surpassing the estimated $0.01 by +73.01%, while revenue for the quarter reached $186.67m , beating expectations by +1.16%.
Earnings released on 17 Feb 2026
EPS came in at $0.06 surpassing the estimated $0.04 by +50.00%, while revenue for the quarter reached $190.17m , beating expectations by +0.89%.
Earnings released on 28 Oct 2025
EPS came in at $0.03 surpassing the estimated $0.02 by +50.00%, while revenue for the quarter reached $187.80m , missing expectations by -0.24%.
Earnings released on 29 Jul 2025
EPS came in at $0.03 matching the estimated $0.03, while revenue for the quarter reached $181.33m , missing expectations by -1.37%.
Earnings released on 29 Apr 2025
EPS came in at -$0.08 falling short of the estimated -$0.02 by -300.00%, while revenue for the quarter reached $168.04m , missing expectations by -8.14%.
Earnings released on 18 Feb 2025
EPS came in at $0.04 surpassing the estimated $0.03 by +33.33%, while revenue for the quarter reached $172.00m , missing expectations by -0.34%.
Earnings released on 5 Nov 2024
EPS came in at $0.05 surpassing the estimated $0.01 by +316.67%, while revenue for the quarter reached $167.82m , missing expectations by -3.04%.
Earnings released on 29 Jul 2024
EPS came in at $0.03 surpassing the estimated $0.00 by +880.39%, while revenue for the quarter reached $164.50m , missing expectations by -1.28%.
Earnings released on 30 Apr 2024
EPS came in at -$0.02 falling short of the estimated -$0.01 by -59.24%, while revenue for the quarter reached $156.24m , missing expectations by -3.69%.
Earnings released on 20 Feb 2024
EPS came in at $0.03 surpassing the estimated $0.01 by +220.51%, while revenue for the quarter reached $155.55m , beating expectations by +1.98%.
Earnings released on 6 Nov 2023
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%, while revenue for the quarter reached $151.95m , beating expectations by +7.01%.
Earnings released on 8 Aug 2023
EPS came in at -$0.05 surpassing the estimated -$0.10 by +50.00%, while revenue for the quarter reached $146.92m , beating expectations by +6.91%.
Earnings released on 8 May 2023
EPS came in at -$0.09 surpassing the estimated -$0.14 by +35.71%, while revenue for the quarter reached $137.22m , beating expectations by +8.57%.
Earnings released on 23 Feb 2023
EPS came in at -$0.06 surpassing the estimated -$0.15 by +60.00%, while revenue for the quarter reached $138.71m , beating expectations by +6.72%.
Earnings released on 8 Nov 2022
EPS came in at -$0.14 surpassing the estimated -$0.19 by +26.32%, while revenue for the quarter reached $128.78m , beating expectations by +5.96%.
Earnings released on 9 Aug 2022
EPS came in at -$0.16 surpassing the estimated -$0.22 by +27.27%, while revenue for the quarter reached $125.07m , beating expectations by +1.74%.
Earnings released on 27 Apr 2022
EPS came in at -$0.20 surpassing the estimated -$0.23 by +13.04%, while revenue for the quarter reached $117.17m , beating expectations by +0.39%.
Earnings released on 23 Feb 2022
EPS came in at -$0.14 falling short of the estimated -$0.13 by -7.69%, while revenue for the quarter reached $125.73m , missing expectations by -0.01%.
Earnings released on 4 Nov 2021
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $121.34m , missing expectations by -4.15%.
Earnings released on 6 Aug 2021
EPS came in at -$0.01 surpassing the estimated -$0.05 by +80.00%, while revenue for the quarter reached $121.72m , meeting expectations.
NEO Stock Performance
Access detailed NEO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
